Biomea Fusion (BMEA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Covalent Small Moleculessrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 4.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 20.87% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
- Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
- Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
- Biomea Fusion Announces Termination of Proposed Public Offering of Securities
- Biomea Fusion Announces Proposed Public Offering of Securities
- After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
- Biomea Fusion to Participate in Upcoming Investor Conferences
- Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biomea Fusion.
Full BMEA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.